October 22, 2025 7:33am

Retail investors may want to be cautious about directional/trending equities, keeping 1 finger ready for a BUY ticket and another on a SELL button if the market moves decisively higher or lower

There is no breadline for share pricing and fact-based intelligence!

Pre-open Signals: 3 Positive and 3 Negative Indications with many aftermarkets to pre-open drops

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

Wednesday night’s … RMi Closing Bell: Fleeing … https://www.regmedinvestors.com/articles/14159

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progress.

 

Wednesday: The pre-open Dow futures are DOWN -0.05% or (-24 points), the S&P futures are DOWN -0.01% or (-1 points) and the Nasdaq futures are DOWN -0.15% or (-38 points)

  • Stock futures are down and relatively flat on Wednesday, 10/22
  • European stocks were in negative territory,
  • Asia-Pacific markets traded mixed, Indian markets are closed for a holiday.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed UP +218.16 points or +0.47%, the S&P closed UP +0.22 points or +0.00% while the Nasdaq closed DOWN -36.877 points or -0.16%
  • Monday: The Dow closed UP +515.97 points or +1.12%, the S&P closed UP +71.12 points or +1.07% while the Nasdaq closed UP +310.568 points or +1.37%
  • Last week: the S&P 500 is up +1.7%, the Dow added +1.6% and the Nasdaq+2.1%.
  • Ther previous week: the Dow was down -2%, the S&P down -1% and the Nasdaq +1%,
  • Last month and Q3’s numbers, the S&P 500 Q was up +7% and the month -4.2%, the Nasdaq’s Q is up +11% and the month +5% while the Dow’s Q is up +5% and the month +1%

 

Q4 – 1 neutral, 8 positive and 6 negative closes

  • Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

Economic Data Docket:

  • The September consumer price index report due Friday is another key event traders are awaiting this week, particularly because all other data releases have been suspended during the U.S. government shutdown. The inflation data should give central bankers more information ahead of their upcoming meeting in late October. Markets are widely expecting the Federal Reserve to announce a quarter percentage point reduction in the overnight borrowing rate, and likely another cut in December. <CNBC>

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • October began with a government shutdown and much fewer econs… along with the usual ups, downs
  • Now uncertainty rules

Trending:

Sarepta Therapeutics (SRPT) closed up +$0.30 with a negative -$0.10 or -0.43% pre-open

Moderna (MRNA) closed up +$0.25 with a negative -$0.22 or -0.80% pre-open

CRISPR Therapeutics (CRSP) closed down -$1.65 after Monday’s +$4.82 after Friday’s +$0.72 with a positive +$0.15 or +0.21% pre-open

Intellia Therapeutics (NTLA) closed down -$1.01 after Monday’s +$3.23 with a positive +$0.41 or +1.52% pre-open

uniQure NV (QURE) closed down -$0.85 after Monday’s +$5.92 after Friday’s -$1.99 with a negative -$0.43 or -0.68% pre-open

Beam Therapeutics (BEAM) closed down -$0.73 after Monday’s +$4.64 after Friday’s +$0.19 with a positive +$0.11 or -0.37% pre-open

 

The BOTTOM LINE: I’m opening with another mantra … If you understand probabilities, the inevitable is easier to maneuver

The stock market had a mixed session, but the Dow set a record high.

But, the cell and gene therapy sector (C&GT) fell into the puddle, under sentiments and algorithms’ heavy pressure.

The shutdown enters its 22nd day today, with lawmakers still unable to agree on a funding bill …

  • The shutdown has slammed the brakes on crucial inflation and jobs data key to the Fed's decision making; but the Bureau of Labor Statistics is set to release September's Consumer Price Index, on Friday after a delay of more than a week.

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

October: understand the new “flow” …

New week:

  • 10/21 - Tuesday closed negative with 17 positive, 23 negative and 0 flat
  • 10/20 - Monday closed positive with 34 positive, 4 negative and 2 flats

Last week:

  • 10/17 - Friday closed negative with 11 positive, 28 negative and 1 flat
  • 10/16 - Thursday closed negative with 17 positive, 22 negative and 1 flat
  • 10/15 - Wednesday closed positive with 31 positive, 9 negative and 1 flat
  • 10/14 - Tuesday closed positive with 28 positive, 12 negative and 0 flat
  • 10/13 – Monday closed neutral with 20 positive, 20 negative and 0 flat

 

Q3 Earnings are in the front-view mirror; we are about to start again …!

  • Sector Q3 earnings begin with IQV Holdings (IQV) on 10/28, MiMedx (MDXG) Ionis Pharmaceuticals IONS), AxoGen AXGN) on 10/29 with Supernus Therapeutics (SUPN) on 11/4 followed by Moderna (MRNA) on 11/6

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.